Friday, December 08, 2017 -- Sweat chloride, a diagnostic characteristic of CF, was also considerably reduced with ivacaftor treatment. Median baseline sweat chloride levels were 104.1mmol/L.
Wednesday, December 13, 2017 -- Two phase 3 double blind, randomised, placebo-controlled trials published in the New England Journal of Medicine show that treatment with the combination of tezacaftor-ivacaftor in patients with cystic fibrosis aged 12 years and older who have the common cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation, Phe508del, is both safe and efficacious.
Monday, December 11, 2017 -- CAMBRIDGE, Mass., Dec. 11, 2017 -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis...
Thursday, December 14, 2017 -- Biochemists at the University of Zurich have used cryo-electron microscopy to determine the detailed architecture of the chloride channel TMEM16A. This protein is a promising target for the development of effective drugs to treat cystic fibrosis.